
501 - 1000 employees
🧬 Biotechnology
💊 Pharmaceuticals
💰 $450M Post-IPO Debt - BioCryst Pharmaceuticals on 2023-04
Biotechnology • Pharmaceuticals
BioCryst Pharmaceuticals, Inc. is a global biotechnology company focused on the discovery, development, and commercialization of novel oral small-molecule and protein therapeutics for rare diseases, notably hereditary angioedema (HAE). Founded in 1986, BioCryst uses structure-guided drug design, medicinal chemistry, and advanced technologies to develop first-in-class or best-in-class medicines, and works closely with patients, advocacy groups, and global partners to bring treatments to market.
🕒 3 days ago
Director leading drug product development for BioCryst’s biologics portfolio. Overseeing formulation, process development, and collaboration with external partners.
🌲 North Carolina – Remote
💰 $450M Post-IPO Debt - BioCryst Pharmaceuticals on 2023-04
⏰ Full Time
🔴 Lead
👔 Director
🕒 June 23
Leads translational modeling efforts for drug discovery at BioCryst, applying mechanistic PK, PBPK, PK/PD, and QSP approaches.
🌲 North Carolina – Remote
💰 $450M Post-IPO Debt - BioCryst Pharmaceuticals on 2023-04
⏰ Full Time
🟠 Senior
🌎 Translator / Interpreter
🕒 June 11
Director, Quality Control overseeing all QC activities for drug development and manufacturing. Ensuring compliance with global regulations and providing technical leadership in pharmaceutical quality control.
🌲 North Carolina – Remote
💰 $450M Post-IPO Debt - BioCryst Pharmaceuticals on 2023-04
⏰ Full Time
🔴 Lead
👔 Director
🕒 June 5
Sr. Commercial Data Operations Manager at BioCryst owning data operations for rare diseases. Managing data integration and risk for a growing portfolio of products.
🌲 North Carolina – Remote
💰 $450M Post-IPO Debt - BioCryst Pharmaceuticals on 2023-04
⏰ Full Time
🟠 Senior
⚙️ Operations
🕒 April 11
R&D Business Operations Manager supporting the Chief R&D Officer in a biotech company. Overseeing operational excellence and strategic communication while managing logistics for the leadership team.
🌲 North Carolina – Remote
💰 $450M Post-IPO Debt - BioCryst Pharmaceuticals on 2023-04
⏰ Full Time
🟡 Mid-level
🟠 Senior
⚙️ Business Operations